Ultragenyx Pharmaceutical Inc. (RARE)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Ultragenyx Pharmaceutical Inc. chart...

About the Company

ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d

CEO

Emil Kakkis

Exchange

NASDAQ

Website

https://www.ultragenyx.com/

$332M

Total Revenue

2K

Employees

$4B

Market Capitalization

-4.98

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $RARE News

Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical

15h ago, source:

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $92.75, along ...

Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet

9d ago, source: Seeking Alpha

Ultragenyx's stock has increased by approximately 9% but lags behind the S&P's return of 28%. The article assesses Ultragenyx ...

Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE)

7d ago, source: Yahoo Finance

Director Matthew Fust has sold 12,195 shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on March 7, 2024, according to a recent SEC filing. The transaction was executed at an average price of ...

RARE Apr 2024 50.000 put

2d ago, source: Yahoo Finance

Thomas Kassberg, the Chief Business Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), has sold 11,509 shares of the company on March 11, 2024, according to a recent ...

10 Biotech Stocks with Huge Potential

10d ago, source: Insider Monkey

Novato, California-based Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is a is a biopharmaceutical company focused on the ...

Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ...

6d ago, source: Yahoo Finance

Thomas Kassberg, the Chief Business Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), has ...

What’s next for AAV gene therapies in 2024?

5d ago, source: Pharmaceutical Technology on MSN

Upcoming regulatory events for pipeline AAV gene therapies, with a focus on neuromuscular and blood disorders, are setting ...

Signal Group buys out Wiley

5d ago, source:

Blake Androff will serve as Signal Group's chief executive, while Chelsea Koski will become president, overseeing day-to-day operations.

BioMarin Subpoena Potentially Signals Continued Investigations into Sponsored Testing Programs

11d ago, source: The National Law Review

You are responsible for reading, understanding and agreeing to the National Law Review's (NLR’s) and the National Law Forum LLC's Terms of Use and Privacy Policy ...

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Arcellx Inc (ACLX) and Exact Sciences (EXAS)

4d ago, source: Business Insider

Allen covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and Crispr Therapeutics AG. The word on The Street in general, suggests a Strong Buy ...

FibroBiologics Appoints Ruben A. Garcia as General Counsel

12d ago, source:

"The addition of Ruben as our General Counsel represents a significant milestone for FibroBiologics in its journey as a publicly traded company," said Mr. O'Heeron. "His experience, particularly in ...

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

7d ago, source: Seeking Alpha

Please subscribe to my Seeking Alpha Marketplace Service "Biotech Analysis Central", whereby you can subscribe to either my "Full Tier" at $399/yr or my "Basic Tier" service at $299/yr instead. If you ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...